Comparative toxicity and toxicokinetic studies of oxiracetam and (S)-oxiracetam in dogs

References

• Agency, EM. (1994). Investigation of chiral active substances. http://www.ema.europa.eu/pdfs/human/qwp/3cc29aeu.pdf. [Accessed 21 Jun 2018].
   Google Scholar
• Baumann P, Eap CB. (2001). Enantiomeric antidepressant drugs should be considered on individual merit. Human psychopharmacol 16:S85–S2.
   PubMed Web of Science ®Google Scholar
• Bottini G, Vallar G, Cappa S, et al. (1992). Oxiracetam in dementia - a double-blind, placebo-controlled study. Acta Neurologica Scandinavica 86:237–41.
   PubMed Web of Science ®Google Scholar
• Branch SK. (2005). Guidelines from the International Conference on Harmonisation (ICH). J Pharm Biomed Anal 38:798–805.
   PubMed Web of Science ®Google Scholar
• Brocks DR. (2006). Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharma drug disposition 27:387–406.
   PubMed Web of Science ®Google Scholar
• Burke D, Henderson DJ. (2002). Chirality: a blueprint for the future. Br J Anaesthesia 88:563–76.
   PubMed Web of Science ®Google Scholar
• Calcaterra A, D'Acquarica I. (2018). The market of chiral drugs: chiral switches versus de novo enantiomerically pure compounds. J Pharm Biomed Anal 147:323–40.
   PubMed Web of Science ®Google Scholar
• Choi S-O, Jung S-H, Um S-Y, et al. (2005). Stereochemical issues in chiral drug development. J Pharma Invest 35:57–63.
   Google Scholar
• Fan W, Li X, Huang L, et al. (2018). S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating alpha 7 nAChR and PI3K/Akt/GSK3 beta signal pathway in rats. Neurochem Int 115:50–60.
   PubMed Web of Science ®Google Scholar
• Health Canada (2000). Stereochemical issues in chiral drug development. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/chem/stereoe.html. [Accessed 22 Jun 2018].
   Google Scholar
• Hu S, Shi J, Xiong W, et al. (2017). Oxiracetam or fastigial nucleus stimulation reduces cognitive injury at high altitude. Brain Behavior 7(10).
   Web of Science ®Google Scholar
• Hutt AJ. (2007). Chirality and pharmacokinetics: an area of neglected dimensionality? Drug metabol drug interact 22:79–112.
   PubMedGoogle Scholar
• Kasprzyk-Hordern B. (2010). Pharmacologically active compounds in the environment and their chirality. Chem Soc rev 39:4466–503.
   PubMed Web of Science ®Google Scholar
• Kometani M, Okada M, Takemori E, et al. (1991). Effect of oxiracetam on cerebrovascular impairment in rats. Arzneimittel-Forschung/Drug Res 41:684–9.
   PubMed Web of Science ®Google Scholar
• Li W, Liu H, Jiang H, et al. (2017). (S)-Oxiracetam is the active ingredient in oxiracetam that alleviates the cognitive impairment induced by chronic cerebral hypoperfusion in rats. Scientific Reports 7(1):10052.
   Google Scholar
• Malykh AG, Sadaie MR. (2010). Piracetam and piracetam-like drugs from basic science to novel clinical applications to CNS disorders. Drugs 70:287–312.
   PubMed Web of Science ®Google Scholar
• Mondadori C, Mobius HJ, Borkowski J. (1996). The GABA(B) receptor antagonist CGP 36 742 and the nootropic oxiracetam facilitate the formation of long-term memory. Behaviour Brain Res 77:223–5.
   PubMed Web of Science ®Google Scholar
• Natarajan R, Basak SC. (2011). Numerical descriptors for the characterization of chiral compounds and their applications in modeling biological and toxicological activities. Curr Topics Med Chem 11:771–87.
   PubMed Web of Science ®Google Scholar
• Nicholson CD. (1990). Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101:147–59.
   PubMed Web of Science ®Google Scholar
• Nunez MC, Garcia-Rubino ME, Conejo-Garcia A, et al. (2009). Homochiral drugs: a demanding tendency of the pharmaceutical industry. Curr Med Chem 16:2064–74.
   PubMed Web of Science ®Google Scholar
• Sato J, Doi T, Wako Y, et al. (2012). histopathology of incidental findings in beagles used in toxicity studies. J Toxicol Pathol 25:103–34.
   PubMed Web of Science ®Google Scholar
• Shimazawa R, Nagai N, Toyoshima S, Okuda H. (2008). Present state of new chiral drug development and review in Japan. J health sci 54:23–9.
   Web of Science ®Google Scholar
• Smith SW. (2009). Chiral toxicology: it's the same thing…only different. Toxicological Sci 110:4–30.
   PubMed Web of Science ®Google Scholar
• Son J, Lee J, Lee M, et al. (2004). Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry. J Pharma Biomed Analy 36:657–61.
   PubMedGoogle Scholar
• Srinivas NR. (2004). Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerations. Biomed Chroma 18:759–84.
   PubMed Web of Science ®Google Scholar
• Strong M. (1999). FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs. Food drug law J 54:463–87.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu B, Zhang Q. (2018). Nerve growth factor in combination with Oxiracetam in the treatment of hypertensive cerebral hemorrhage. Pak J Med Sci 34:73–7.
   PubMed Web of Science ®Google Scholar
• Villardita C, Grioli S, Lomeo C, et al. (1992). Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multinfarct dementia of mild to moderate degree. Neuropsychobiol 25:24–8.
   PubMed Web of Science ®Google Scholar
• Wainer I. (1992). FDA’s policy statement for the development of new stereoisomeric drugs. In: Wainer, I., ed. Chirality. CA: Wiley, 4:338–40.
   Google Scholar
• Wan X, Wang H, Ma P, et al. (2014). Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC-MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration. J chroma B Analyt technol biomed life sci 969:95–100.
   PubMed Web of Science ®Google Scholar
• Wang W, Ji H, Li T, et al. (2016). Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs. Acta Pharma 66:279–87.
   PubMed Web of Science ®Google Scholar
• Wang C, Li F, Guan Y, et al. (2014). Bone marrow stromal cells combined with oxiracetam influences the expression of B-cell lymphoma 2 in rats with ischemic stroke. J Stroke Cerebrovascul Dis 23:2591–7.
   PubMed Web of Science ®Google Scholar
• Yan C, Peng S. (2008). Toxicological characteristics of chiral drugs and their toxicology evaluation Chin J New Drugs 17:1372–4.
   Google Scholar
• Yi X, Jin G, Tian M, et al. (2016). The effect of oxiracetam on neurogenesis in the hippocampus after traumatic brain injury. Brain Injury 30:749.
   Web of Science ®Google Scholar
• Zhang Q, Yang W, Yang Y, et al. (2015a). Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method. J Pharm Biomed Anal 111:153–8.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yang W, Zhang Q, et al. (2015b). Enantioselective HPLC determination of oxiracetam enantiomers and application to a pharmacokinetic study in beagle dogs. J Chroma B-Analyt Technol Biomed Life Sci 993:9–13.
   PubMed Web of Science ®Google Scholar